Novo Nordisk is launching a discounted subscription plan for self-funding patients in the United States using its obesity medication, Wegovy, in a strategic effort to broaden access and regain market share from competitor Eli Lilly. The new programme, available from Tuesday through telehealth platforms such as Ro and WeightWatchers, provides fixed monthly prices for three-, six-, or 12-month supplies, with longer-term plans offering more significant reductions.
Pricing Details and Market Competition
Under the subscription plan, Wegovy injection pens will cost $329 per month for a three-month commitment, $299 for six months, and $249 for a 12-month subscription. This represents discounts ranging from 6% to 29% compared to the standard monthly self-pay price of $349. This initiative follows Novo Nordisk's previous 30% price cut for Wegovy's standard monthly self-pay price in November, highlighting a strategic pivot towards direct-to-consumer sales and telehealth integration.
Strategic Shift and Industry Impact
The move intensifies competition in the obesity drug market, where both Novo Nordisk and Eli Lilly are leveraging direct sales strategies to attract patients, discourage them from opting for cheaper compounded alternatives, and promote longer treatment durations. Experts caution that weight-loss injections like Wegovy may need to be taken for life, underscoring the importance of affordable and accessible long-term plans. This subscription model aims to address these concerns by making the medication more financially viable for patients over extended periods.
By offering tiered discounts, Novo Nordisk seeks to enhance patient retention and loyalty, potentially reshaping how obesity treatments are marketed and consumed in the healthcare sector. The reliance on telehealth platforms also reflects broader trends in digital health, making it easier for patients to manage their prescriptions remotely.
